TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study

Trial Profile

TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Amfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Tris Pharma
  • Most Recent Events

    • 09 Feb 2017 According to a Tris Pharma media release, were presented at the 2017 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.
    • 09 Feb 2017 Primary endpoint has been met. (SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale)), as reported in a Tris Pharma media release.
    • 09 Feb 2017 Results published in the Tris Pharma Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top